The development of the RTS,S malaria vaccine candidate: challenges and lessons

W R Ballou1

  • 1Infectious Diseases Development, Global Health Division, Bill & Melinda Gates Foundation, PO Box 23350, Seattle, WA, USA. rip.ballou@gatesfoundation.org

Parasite Immunology
|August 21, 2009
PubMed

Insights

The RTS,S malaria vaccine candidate aims to protect young children in Africa from Plasmodium falciparum. Ongoing trials and Phase II data suggest it could significantly reduce malaria burden when integrated into immunization programs.

Area of Science:

  • Vaccinology
  • Infectious Disease Control
  • Pediatric Health

Background:

  • Malaria remains a significant threat to infants and young children in sub-Saharan Africa.
  • Plasmodium falciparum is a primary cause of severe malaria in endemic regions.
  • Developing a safe and effective malaria vaccine for widespread use presents unique challenges.

Observation:

  • The RTS,S vaccine candidate is the most advanced globally for malaria prevention.
  • A pivotal Phase III efficacy trial of RTS,S is currently underway in Africa.
  • Phase II program data show encouraging results for vaccine efficacy and safety.

Findings:

  • The RTS,S vaccine is designed for administration through the Expanded Program for Immunization (EPI).
  • The vaccine aims to reduce the risk of clinical malaria disease in early life.
  • Potential for reducing severe malaria and associated co-morbidities is being investigated.

Implications:

  • RTS,S could become a crucial new tool in combating malaria in sub-Saharan Africa.
  • Successful vaccine deployment may significantly decrease the burden of childhood malaria.
  • The development highlights the complexity of novel vaccine technologies and the importance of global health partnerships.

Related Concept Videos

Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Symbiosis00:58

Symbiosis

Symbiotic relationships are long-term, close interactions between individuals of different species that affect the distribution and abundance of those species. When a relationship is beneficial to both species, this is called mutualism. When the relationship is beneficial to one species but neither beneficial nor harmful to the other species, this is called commensalism. When one organism is harmed to benefit another, the relationship is known as parasitism. These types of relationships often...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.